Normal 0 21 false false false MicrosoftInternetExplorer4


Normal 0 21 false false false MicrosoftInternetExplorer4


Institut National de la Santé et de la Recherche Médicale – U1048

Further Information : and




General Description

Founded in 1964, the French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research. Inserm has a 13,000 person workforce. Inserm’s unit 1048 (Institute of Cardiovascular and Metabolic Diseases (I2MC)) in Toulouse focuses on metabolic, cardiovascular and renal diseases. The main feature of the I2MC is the collaboration of basic scientists and clinicians working on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (thrombosis, atherosclerosis, cardiac and renal failure). The I2MC is composed of 13 research teams employing over 280 people (scientists, physicians, engineers, technicians, students, postdocs and administrators).
The research programs of Team 12 of I2MC concentrate on pathophysiology and detection of renal and vascular diseases focussing on fibrosis. The team has significant expertise in multi biological level omics data gathering (miRNomics, transcriptomics, proteomics, peptidomics, metabolomics) and annotation and has, based on these analyses, identified several potential antifibrotic targets (e.g. kinin receptors, arginases, hepatocyte nuclear factors).

Key Personnel






Joost P Schanstra, Ph.D is director of research at Inserm U1048 in Toulouse (France) focusing on renal fibrosis and early detection of renal disease. He received his PhD in 1996 from the University of Groningen, The Netherlands. He has published extensively on the use of -omics (mostly proteomics) to study and detect renal disease. He also initiated the elaboration of an extensive knowledge base on –omics data in kidney disease, accessible to the public at







Jean-Loup Bascands, Ph.D, director of research at Inserm U1048, born in 1960 received its PhD in Physiology (1985) from the University Paul Sabatier in Toulouse. Since 1994 he is group leader at Inserm. Over the last 15 years he has extensively published on renal fibrosis, its mechanism(s) and has identified several new targets in the development of renal fibrosis.





Benedicte Buffin-Meyer, Ph.D. started her research career by studying mechanisms of renal ATPases adaptation in response to potassium disorders (CNRS-CEA/Paris-Saclay) and received her PhD in Life Sciences (1996) from the University Paris-Sud/Orsay. In 1999, she became associate professor at the University Paul Sabatier/ Toulouse: after research on alpha2-adrenergic signalization (Inserm U388), she returned to the “kidney” by joining the renal fibrosis team at the I2MC/ Toulouse. She is a specialist in fluid shear stress and renal physiology.


The laboratory has been/is participating in a number of omics-based European projects including e-LICO (2000-2012), Protoclin (2010-2014), EUReNomics (2013-2017), Biomargin (2013-2017), Sysvasc (2014-2019). ESR5 will be trained at the Inserm laboratory





© Copyright 2018 | Legal Notice